Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Zhu, Yanyun ^a   Yang, Junlan ^a   Jiao, Shunchang ^a   Ji, Tiefeng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Ganglioside monosialic acid; Gastrointestinal tumors; Neurotoxicity; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GANGLIOSIDE MONOSIALIC ACID; NEUROPROTECTIVE AGENT; OXALIPLATIN; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GASTROINTESTINAL TUMOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; G(M1) GANGLIOSIDE; GASTROINTESTINAL NEOPLASMS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SIALIC ACIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872769068     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-19     Document Type: Article

References (35)

1. Zhao Q, Zhang H, Li Y, Liu J, Hu X, Fan L. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res 2010, 29:118-130. 10.1186/1756-9966-29-118, 2939545, 20799994.
2. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005, 5:116-125. 10.1186/1471-2407-5-116, 1266024, 16168057.
3. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplat in alters voltage gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000, 406:25-32. 10.1016/S0014-2999(00)00667-1, 11011028.
4. Ali BH. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature. Basic Clin Pharmacol Toxicol 2010, 106:272-279.
5. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001, 85:1219-1225. 10.1054/bjoc.2001.2024, 2375155, 11710838.
6. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003, 30(4 Suppl 15):5-13.
7. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005, 39:128-135.
8. Hochster HS, Grothey A, Childs B. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007, 25:4028a-4029a.
9. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008, 26:1188-1189. 10.1200/JCO.2007.15.3767, 18309961.
10. Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 2008, 42:1481-1485. 10.1345/aph.1L179, 18698011.
11. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003, 9:5756-5767.
12. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011, 2011:843019-843026. 3265255, 22312559.
13. Ferrari G, Anderson BL, Stephens RM, Kaplan DR, Greene LA. Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem 1995, 270:3074-3080. 10.1074/jbc.270.7.3074, 7852388.
14. Leon A, Lipartiti M, Seren MS, Lazzaro A, Mazzari S, Koga T, Toffano G, Skaper SD. Hypoxic-ischemic damage and the neuroprotective effects of GM1 ganglioside. Stroke 1990, 21:III95-III97.
15. Skaper SD, Facci L, Schiavo N, Vantini G, Moroni F, Dal Toso R, Leon A. Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease. J Pharmacol Exp Ther 1992, 263:1440-1446.
16. Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson's disease: results of a five year open study. J Neurol Sci 2010, 292:45-51. 10.1016/j.jns.2010.02.009, 20206941.
17. Kakinoki B, Sekimoto S, Yuki S, Ohgami T, Sejima M, Yamagami K, Saito K. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 2006, 55:616-621. 10.2337/diabetes.55.03.06.db05-1091, 16505223.
18. Fighera MR, Royes LF, Furian AF, Oliveira MS, Fiorenza NG, Frussa-Filho R, Petry JC, Coelho RC, Mello CF. GM1 ganglioside prevents seizures, Na+, K+-ATPase activity inhibition and oxidative stress induced by glutaric acid and pentylenetetrazole. Neurobiol Dis 2006, 22:611-623. 10.1016/j.nbd.2006.01.002, 16516483.
19. Huang F, Dong X, Zhang L, Zhang X, Zhao D, Bai X, Li Z. The neuroprotective effects of NGF combined with GM1 on injured spinal cord neurons in vitro. Brain Res Bull 2009, 79:85-88. 10.1016/j.brainresbull.2008.12.007, 19133317.
20. Zakharova IO, Sokolova TV, Furaev VV, Rychkova MP, Avrova NF. Effects of oxidative stress inducers, neurotoxins, and ganglioside GM1 on Na+, K+-ATPase in PC12 and brain synaptosomes. Zh Evol Biokhim Fiziol 2007, 43:148-154.
21. Huang F, Dong X, Zhang L, Zhang X, Zhao D, Bai X, Li Z. GM1 and nerve growth factor modulate mitochondrial membrane potential and neurofilament light mRNA expression in cultured dorsal root ganglion and spinal cord neurons during excitotoxic glutamate exposure. J Clin Neurosci 2010, 17:495-500. 10.1016/j.jocn.2009.07.112, 20171893.
22. Chentanez V, Thanomsridejchai N, Duangmardphon N, Agthong S, Kaewsema A, Huanmanop T, Maneesri S. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai 2009, 92:50-57.
23. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen PM. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319. 10.1634/theoncologist.12-3-312, 17405895.
24. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, Colman LK, Lanier KS, Pajon ER, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 25:2205-2211. 10.1200/JCO.2006.08.6652, 17470850.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
26. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010, 6:657-666. 10.1038/nrneurol.2010.160, 21060341.
27. Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011, 10:407-417. 10.1517/14740338.2011.543417, 21210753.
28. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392. 10.1002/mus.10559, 14981738.
29. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2002, 20:3478-3483. 10.1200/JCO.2002.07.061, 12177109.
30. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001, 12:421-422. 10.1023/A:1011184609963, 11332158.
31. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011, 29:421-427. 10.1200/JCO.2010.31.5911, 3058288, 21189381.
32. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxalipatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. 10.1056/NEJMoa032709, 15175436.
33. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005, 16:1147-1151. 10.1093/annonc/mdi222, 15849224.
34. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394-400. 10.1200/JCO.2005.03.0106, 16421419.
35. Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002, 13:1315-1318. 10.1093/annonc/mdf254, 12181257.